This company listing is no longer active
McKesson Europe Resultados de beneficios anteriores
Pasado controles de criterios 0/6
McKesson Europe's earnings have been declining at an average annual rate of -2039.3%, while the Healthcare industry saw earnings growing at 3.8% annually. Revenues have been growing at an average rate of 8.7% per year.
Información clave
-2,039.3%
Tasa de crecimiento de los beneficios
-2,039.3%
Tasa de crecimiento del BPA
| Crecimiento de la industria Healthcare | 15.7% |
| Tasa de crecimiento de los ingresos | 8.7% |
| Rentabilidad financiera | -2.0% |
| Margen neto | -0.6% |
| Última actualización de beneficios | 31 Mar 2022 |
Actualizaciones de resultados anteriores recientes
Recent updates
Estimating The Fair Value Of McKesson Europe AG (HMSE:CLS1)
Dec 23
These Return Metrics Don't Make McKesson Europe (HMSE:CLS1) Look Too Strong
Sep 01These Return Metrics Don't Make McKesson Europe (HMSE:CLS1) Look Too Strong
May 19McKesson Europe (HMSE:CLS1) Could Be Struggling To Allocate Capital
Jan 27Capital Allocation Trends At McKesson Europe (HMSE:CLS1) Aren't Ideal
Sep 07McKesson Europe (HMSE:CLS1) Will Be Looking To Turn Around Its Returns
Apr 29What You Need To Know About McKesson Europe AG's (HMSE:CLS1) Investor Composition
Mar 20Is McKesson Europe AG (HMSE:CLS1) A Risky Dividend Stock?
Feb 13
Desglose de ingresos y gastosBeta
Cómo gana y gasta dinero McKesson Europe. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Mar 22 | 9,257 | -54 | 450 | 0 |
| 31 Mar 21 | 8,518 | 3 | 484 | 0 |
| 31 Mar 20 | 17,118 | -71 | 1,146 | 0 |
| 31 Mar 19 | 16,417 | -47 | 1,159 | 0 |
| 31 Mar 18 | 21,090 | -303 | 1,416 | 0 |
| 31 Mar 17 | 20,644 | -807 | 1,260 | 0 |
| 31 Dec 16 | 20,475 | -76 | 2,333 | 0 |
| 30 Sep 16 | 21,118 | 437 | 1,354 | 0 |
| 30 Jun 16 | 21,265 | 459 | 1,387 | 0 |
| 31 Mar 16 | 21,193 | 487 | 1,428 | 0 |
| 31 Mar 15 | 21,076 | 129 | 1,352 | 0 |
| 31 Dec 14 | 20,647 | 187 | 1,347 | 0 |
| 30 Sep 14 | 21,877 | 79 | 1,454 | 0 |
| 30 Jun 14 | 21,606 | 64 | 1,443 | 0 |
| 31 Mar 14 | 21,426 | 167 | 1,422 | 0 |
| 31 Dec 13 | 21,408 | 165 | 1,419 | 0 |
| 30 Sep 13 | 21,565 | 146 | 1,392 | 0 |
| 30 Jun 13 | 21,753 | 153 | 1,389 | 0 |
| 31 Mar 13 | 21,990 | 99 | 1,418 | 0 |
| 31 Dec 12 | 22,271 | 103 | 1,428 | 0 |
| 30 Sep 12 | 22,339 | 51 | 1,447 | 0 |
| 30 Jun 12 | 22,347 | 72 | 1,440 | 0 |
Ingresos de calidad: CLS1 is currently unprofitable.
Margen de beneficios creciente: CLS1 is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: Insufficient data to determine if CLS1's year-on-year earnings growth rate was positive over the past 5 years.
Acelerando crecimiento: Unable to compare CLS1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: CLS1 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-23.9%).
Rentabilidad financiera
Alto ROE: CLS1 has a negative Return on Equity (-1.96%), as it is currently unprofitable.